The Filing Desk

Sutro Biopharma

STRO · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

STRO · Last close · November 19, 2026
$8.72
Value Sutro Biopharma yourself

Sutro Biopharma's revenue rose 65.2% to $102 million in fiscal 2025. Its operating margin was −154.5%, up from −384.3% a year earlier. The diluted share count rose 9.8%.

SUTRO BIOPHARMA, INC. Latest fiscal year ended December 31, 2025 10-K filed March 23, 2026 · 0001193125-26-119873 Updated
Revenue
$102M
65.2%
Operating margin
−154.5%
229.8 pts
Net income
−$191M
 
Free cash flow
—
 
Return on equity
—
 
Market cap
$145M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Share counts and per-share figures for earlier years are restated for a stock split (1-for-10), so every year is on today's share basis. Return on equity for fiscal 2025 is blank: the 10-K's structured data doesn't include every figure it needs. Interest coverage for fiscal 2025 is blank: the 10-K's structured data has no interest expense for that year.

Charts show fiscal years, from the 10-K filings.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Sutro Biopharma lost money in fiscal 2025: a net loss of $191 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments161302334317141
Debt incl. finance leases2516400
Net debt (negative means net cash)−136−286−330−317−141
Net debt to EBITDA—————
Debt to equity0.1x0.1x0.0x0.0x—
Interest coverage−37.9x−53.7x−68.7x−769.2x—
Current ratio5.2x5.3x4.5x2.6x2.0x
Quick ratio5.2x5.3x4.5x2.6x2.0x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Sutro Biopharma's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

No officer, director or 10% owner of Sutro Biopharma reported buying or selling its shares on the open market between November 20, 2025 and November 19, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score3 of 82 of 82 of 8
Rule of 40———
Altman Z''−0.09−7.04−22.06
Accruals ratio1.1%−8.4%−4.9%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets rosePassFailFail
Cash from operations exceeds net incomeFailPassPass
Debt fell relative to assetsPassPassFail
Current ratio roseFailFailFail
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsPassFailPass
F-score3 of 82 of 82 of 8
Companies that report no gross profit are scored on the other eight.

Compare

Put Sutro Biopharma side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Sutro BiopharmaFY2565.2%−154.5%———2
Century TherapeuticsFY251,556.8%−15.8%−95.9%———Compare
ImmunityBioFY25668.3%−226.0%−272.6%——3Compare
AgenusFY2510.4%−17.7%−67.6%——3Compare
CytokineticsFY25376.6%−695.4%−607.5%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue6052384343626815462102
Revenue growth—−13.4%−25.8%11.2%−0.0%44.8%9.5%126.8%−59.6%65.2%
Gross profit——————————
Research and development4455546677104137180252166
Operating income1−19−37−56−71−98−129−89−238−158
Net income2−20−35−119−32−106−119−107−228−191
Diluted EPS (US$)0.00−439.50−61.30−24.30−9.90−22.90−23.50−17.80−29.40−22.49
Diluted shares (millions)0012355688
Cash flow
Cash from operations−13−3713−65−68−824−112−192−177
Capital expenditure432———————
Free cash flow−18−4011———————
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation11310122326252514
Balance sheet at fiscal year end
Cash and short-term investments1222204118326161302334317141
Debt incl. finance leases——159242516400
Total assets—41223156394341407471387174
Total liabilities—4792596289190321343306
Shareholders' equity−91−1091329833225321715045−132
Margins and ratios
Gross margin——————————
Operating margin2.3%−37.2%−96.9%−129.8%−166.3%−159.2%−190.3%−58.1%−384.3%−154.5%
Net margin2.9%−38.0%−91.9%−278.9%−75.2%−170.6%−175.9%−69.5%−366.6%−186.4%
Free cash flow margin−29.4%−78.1%29.0%———————
Rule of 40 (growth + FCF margin)—−91.4%3.2%———————
Return on capital—————−105.9%————
Return on equity——−313.4%−104.0%−14.9%−36.1%−50.8%−58.2%−234.2%—
Return on assets——−26.8%−62.8%−11.7%−28.7%−31.9%−24.3%−53.0%−68.1%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Sutro Biopharma's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Sutro Biopharma.